Good morning, everyone. I'm delighted to welcome you to our 2024 Interim Results Presentation. With me this morning is Soraya Benchikh, our new CFO, and Victoria Buxton, Group Head of Investors Relations. I will begin with our transformation highlights and the progress we have made against our key areas of focus over the last 12 months. Soraya will then take you through our financial performance in more detail. I will then return to talk more about our performance outlook before we move to the Q&A session. With that, I'd like to draw your attention to the disclaimers on Slides 2 and 3. So let's begin by looking at the way forward. Our first half performance is in line with expectations, and we are on track to deliver our full year guidance. In the first half of this year, we have continued to transform our business. We added 1.4 million smokeless consumers, reaching 26.4 million. Smokeless now accounts for 18% of group revenue, up 1.4 percentage points versus full year ‘23. Our focus on quality growth, balancing top and bottom line delivery, has driven a GBP165 million increase in new category contribution, and close to a 10 percentage point increase in our category contribution margin. Building on this momentum, we expect another good increase in new category contribution for the full year. We are committed to rewarding shareholders with strong cash returns, and I'm pleased with our progress in enhancing financial flexibility, enabling the initiation of a sustainable share buyback. This year is a key moment in our transformation journey, as we sharpen our execution, enabling us to navigate near-term market challenge and drive our sustainable transformation. Turning to the drivers of 2024 delivery. As we previously guided, 2024 is an investment year for BAT. In the first half, we have invested to strengthen our U.S. business, accelerate innovation momentum, and enhance capabilities that support our strategic delivery. This, together with lapping a tough comparator in APMEA, means we expect an acceleration in our second half performance. I'm encouraged that our new category launchings and our first half U.S. investments are gaining traction. Together with the expected unwind of U.S. wholesale inventory movements related to the year-on-year timing of our first half price increase, I'm confident that we are on track to deliver our full year guidance. This time last year, I shared a clear set of objectives to sharpen our execution and build a more modern and agile BAT. Over the last 12 months, working together with our broader teams, we have made good progress across these six areas of focus. We will touch on some of these highlights in more detail as we go through today's presentation. While there is still more to do, we are making good progress, and I'm confident that the choice we have made and actions we are taking are the right way forward for BAT. And with that, I will hand over to Soraya to take you through the detail of our results.

Thank you, Tadeu, and good morning, everyone. I'm Soraya Benchikh, CFO of BAT. And before I take you through the results, I would like to introduce myself. I'm Lebanese, and having started my career in finance at Gillette and GE. I then spent many years working at BAT across Europe, Russia, Africa, and the Middle East. I have spent the last 12 years in general management, and my last four have been at Diageo, culminating in my role as President for Europe. Now, after two months back at BAT, I'm excited to join Tadeu and the team to work on the next stage of our transformation. As CFO, my focus will be on supporting BAT's transformation with financial stability and effective resource allocation. This includes driving quality growth by balancing top and bottom line performance and targeting investments to deliver better returns and consistent cash generation. I will do so by prioritizing understanding market trends and consumer needs, investing in innovation and R&D, streamlining operations for efficiencies, while managing organizational change effectively and aligning with our sustainability goals. I am passionate about transformative leadership and committed to fostering creative, inclusive, and empowered teams. Maintaining transparent and consistent communication with stakeholders is also key for me. And I really look forward to sharing insights into our performance and future outlook with you. Now, moving to our first half results. Our reported results reflect the impact of our exit from Russia and Belarus in September last year, higher amortization and impairment charges following the decision to start amortizing the U.S. acquired combustible brands from January 2024, and a gain recognized in respect of the partial sale of the group's investment in ITC. Now, to better understand the underlying performance of the business and present a like-for-like comparison, excluding Russia and Belarus, we…

Thank you, Soraya. I would now like to spend a few moments outlining the opportunity and pathway ahead for BAT and why we are confident we can deliver an acceleration in our second half performance. There are four clear accelerators that we expect to drive our second half delivery. Improving U.S. performance, innovations in all three new categories, driving double digit revenue growth for the full year. In addition, we are lapping a softer comparator in APMEA and expect a continuous strong performance in AME. As a result, we remain confident in delivering our guidance for 2024. Looking at the U.S. premium segment, we can see a clear correlation between consumer sentiment and premium segment volume trends. Historic macroeconomic shocks have had a significant impact on consumer sentiment, and this in turn has driven accelerated decline in premium volumes. However, over time, as consumer confidence levels improve, premium volume decline typically stabilize, returning to a more normalized level. Although the U.S. market continues to evolve, we believe this further supports our outlook for improving U.S. delivery over the medium term. A key feature of our industry in recent years has been the strength of the deep discount segment, as consumers look to make their dollars stretch further. We are now starting to see deep discount volume growth slow dramatically, with market share remaining broadly flat since the third quarter of last year. At the same time, the branded value segment has grown volume share, with BAT increasing its segment share led by Lucky Strike. While we have not assumed a macro improvement in our full year guidance, we believe this early indication of low-end consumer recovery could provide a tailwind in the medium term. I want to share some more color on the portfolio actions we have taken, and why…

Thank you, Tadeu, and good morning, everyone. [Operator Instructions] Tadeu and Soraya will be very happy to take your questions. And I will now hand over to the conference call operator.

Thank you. And our first question today comes from Rashad Kawan from Morgan Stanley. Please go ahead.

Hey, good morning, Tadeu and Soraya. Thanks for taking my questions and congrats on the results. A couple for me, both on the U.S., please. On the combustibles market, if I compare to '21, where you laid out the impacts to the market, what you have in the full year, the key deterioration is coming from higher elasticities. Is that purely from increased poly-usage, you think? Or is it just less volume of smokers are cutting back given the pricing environment, a weak sentiment overall? I guess have you seen a material change in consumer elasticity in U.S. combustibles? And then my second question is on Modern Oral again in the U.S. I mean the acceleration we're seeing a bit of a surprise, to be honest, given you still don't have your more superior obviously European product in the U.S. Is it just about the brand refresh you've done? Are you benefiting a little bit from the shortages by one of your peers there? Any more color on what's going on in U.S. Modern Oral, I think. Thanks, again.

Okay, Rashad, look, on the U.S. combustible, we are not seeing a massive deterioration in terms of elasticity in the cigarettes. What is impacting us in the industry as a whole is a combination of a very difficult macro environment. Remember that we came from the pandemic times of a lot of support from state federal level to consumers that was really reversed completely, was taken out completely. And at the same time, the consumer got heated by very high levels of inflation and very high levels of interest rates as well and put mostly low-income consumers under a lot of stress financially. So this clearly has an impact, and it's reflecting the consumer sentiment. That's why we show in our presentation, the correlation. Now there are the obvious driver for that is the proliferation of the illegal vapor single-use products in the U.S. And the category continues to grow despite the fact that the legal part of it is actually reducing now is all the growth is more than compensating the reduction on the legal side and going into those illicit, and this is putting more pressure on that. So these are the major drives that's why we are seeing this high-single digit industry decline in the U.S. It's good to note that we are seeing some first green shoots in terms of the macroeconomics. The inflation is coming down. Weight inflation is catching up and narrowing the gap with the overall inflation. We are seeing a small uptick in consumer sentiment more recently, and this, combined with a potential Fed move in terms of reduced interest rates by end of the year, could all be positive more towards 2025-2026. Now your question about poly-usage is the right one, because at the end, we are seeing more poly-users dynamic…

Thank you very much.

Thank you. We now move on to a question from Gaurav Jain from Barclays. Please go ahead.

Hi, good morning. I have three questions. So first one is for Soraya. So if I look at your FX guidance, there is a 4% headwind, and that has been a structural issue with BAT given your presence in so many emerging markets. It was an issue for a lot of other FMCG companies, and we are now hearing from several companies, including Philip Morris, Unilever, Coke, that they're targeting dollar EPS growth or a pound EPS growth. Is that something which BAT would also like to move to that instead of just a constant currency EPS growth, actually try to have meaningful pound EPS growth?

Sorry, Gaurav. Apologies. I didn't hear the last part of the question. If I understand correctly, are we confident that we can drive EPS growth on constant terms? Was that the question? And current term?

No. Look, I think clearly you have a guidance that you can grow EPS on a constant currency basis. But it is not -- I mean, it has been a struggle to drive pound EPS growth. That is because FX has been a structural headwind, and we are seeing some of your peers, including Philip Morris, now talk of hard currency EPS growth. So is that something which BAT should also do is what I'm trying to understand. And maybe Tadeu, you can also chime in there.

Yes. I am confident, Gaurav, that we can drive EPS growth on current terms. Do you want to add, Tadeu?

Gaurav, look, remember that our numbers, we have a transactional FX on this. Some of these companies you are referring to they come with numbers at constant numbers that actually exclude transaction, which makes a very deep -- even bigger distance between constant and current let's put it that way. So for sure, in years like the ones that we are facing now with a lot of the valuations coming mainly emerging markets, it's difficult to imagine that you can offset all that. But like Soraya said, in the medium term, on a current basis, we should be able to be able to deliver that.

Sure. Thank you. Then the second question I had is on your NGP revenue and volume and how it has panned out in 1H. Your heated tobacco volumes organically are down, and they were down in Japan as well. And you had a lot of price repositioning in 2H '23. And your e-cigarette business is also down. So do you think it makes sense to direct more of the investments into e-cigarettes and away from heated tobacco? Otherwise, both the segments are down.

Look, the situation in AME is impacted, and we referred to that in our presentation by some stock movements that we have done end of last year to prepare for the flavor ban in tobacco heated product because we have to, in some markets start selling view our non-tobacco flavor product. And if you adjust for that, AME, I think, that had a revenue of 2%, a volume of 7%. The volume will be double digits adjusted for that. So I'm very pleased actually with the progress that we are making. You go to place like Poland, for example, we have a read 34% market share in the category. And in difficult places like Italy, we start seeing some improvements. The same happening in Japan. You have to remember that last year -- and I was very clear and transparent about that. So when I came as a CFO, I said we don't have a really competitive THP product, and we are focused in improving our competitiveness in that segment. We managed to sign an IP agreement with PMI early in the year. And we also managed to get in place a product that is well superior. You saw some of the statistics that I present today. And if you consider that the penetration of these devices on average, just -- all these improvements that you saw in my slide about average day consumption, conversion, retention, this will just grow from now until the end of the year, not to mention the other platforms that we are now building our pipeline. So I think the answer is yes, we should be investing. I think that we are lapping a difficult period, mainly because of lack of competitiveness. But I'm quite confident that we have started to have turned our competitive position in THP.

Sure. Thank you so much. And my last question is on e-cigarettes. Clearly, very nice to hear that you have received the PMTA. Could you just remind us what's your PMTA pipeline now on e-cigarettes in the U.S. and clearly Vuse doing pretty well internationally. So how should we think about future PMTAs?

Well, Yeah. PMTA -- well, what we have already approved is basically the tobacco flavors of Alto, Vuse, Ciro and Solo, as you know, is the largest combined PMTAs received in the U.S. so far. We are disputing, as you know, the mental version why we still keep selling, because we believe that we have the data that is necessary for the FDA to be to take into consideration. So we receive the stay, and we are hopeful that this can be reviewed in the future. We have just submitted last month, the PMTA for our age-gated device. This includes not just flavor but also some fruit flavors as well and mantle as part of this. And this is the most pressing PMTAs, I have to say that we are now expecting. We are very hopeful that given the fact that it's an age verified with age verification technology FDA can, as they said, expedite the approval of this PMTA -- but this will be probably 1-2 that they will be considering to trying to bring back flavors that is so critical to move other smokers out of cigarettes to add vapor in a responsible way.

Thank you so much.

Thank you. [Operator Instructions] And up next we have Richard Felton from Goldman Sachs. Please go ahead.

Thank you. Good morning. Two questions from me, please. My first question is on vapor outside of the U.S., where I think volume was down almost 10% in H1. Is there any color or detail you can share on the drivers of that and whether those drivers are one-off in nature? Or there's more structural headwinds that we should be aware of? Then my second question also on new categories. Look, I'd really like to understand how you're thinking about growing revenue versus improving profitability from here? Because if I take a step back and reflect on your performance over the last few years, you've missed your guidance on revenue, but profitability has improved much better than you had been previously guiding for. So looking forward, how do you think about managing your P&L for that part of the business? And how do you balance investing in further growth but also improving margin? Thank you.

Okay. So I will take the second question. In regards to your vapor question outside the U.S. is pretty much impacted by Canada. This is basically Quebec that introduced a new legislation, limiting the amount of 1 ml to 2 ml and banning all flavors other than tobacco, and without any enforcement. So what we saw in the following day was these proliferations of all these illegal products bringing back big tanks full of flavors and for sure, there is no level playing field, and that's the consequence that you are seeing there in Canada. So in a way, it's a one-off until the regulators wake up and trying to enforce properly or review the regulatory element to that. That's why when you see the second pillar of our strategy, it's all about tobacco harm reduction, it is about having evidence science evidence points of discussion with key stakeholders, regulators, policymakers to avoid this type of very misleading regulations to be put in place without proper enforcement. So if you strip out Canada in reality, AME has as a region grew 15% in revenue. And this without any impact of all these products that I show in my slides, the Vuse Go 2.0, the Vuse Go Reload. These are all reaching the market now in May has not any time in terms of the shares or performance that you saw in the performance this early today. And the other markets that we are quite excited about markets like New Zealand that has now moved to a more well-sounded regulatory environment and is allowing us to properly compete in the markets. And we are gaining a lot of traction with our offers in New Zealand. And also Korea, that is quite exciting. We are ready market leaders in a very short period of time in Korea. And we also have prospects like markets like Indonesia. So overall, it's basically in summary, a consequence of the regulatory impact in Canada.

Okay. I'll take the second question. In terms of balancing revenue growth and margin expansion, as you might recall, I mentioned that our priority is really to balance top and bottom line growth. And we're really looking to do this by continuing to invest, but more so targeting our investments in all the categories that have momentum, but also where there is more value, be it in categories or in geographies. So we're targeting investment, what you will see is we'll continue to balance both top and bottom line. And this is evidenced by the fact that in the first half, we showed that we've increased category contribution by more than I think it was around GBP167 million. And that's expanded category contribution by 10 margin points, 10 percentage. So as we go forward, and into the full year, we will continue our targeted investments. And as Tadeu mentioned, we are very second half leaning in terms of innovations coming to market. So we will have quite a lot of investment in the second half, but you will continue to see our category contribution increase year-on-year. And this will be a really big priority for us going forward to target our investments and accrete our margins.

Great. Thank you.

Thank you. And from UBS, we have Faham Baig with our next question. Please go ahead.

Good morning, team. A couple from me as well, please. Could I go back to the increased poly-usage that you're seeing? I think 1 of your competitors mentioned that the consumer conversion rates on vapor are lower than that seen in heated tobacco. I just wanted to get your perspective on what you're seeing on the conversion rates between the two categories and how you generally see the prospects of the categories? And the second question goes back on to U.S. vapor, I know you've previously quantified the growth of the overall category and the impact on cigarette volumes. If you could just remind us on that? And by when do you assume that the increased enforcement efforts by the FDA could negatively impact the development of these disposable products. And if you can touch on this, you've highlighted some benefits in Louisiana as well. What about the other two states that have implemented the registries, Oklahoma and Alabama maybe what you're seeing there would help as well.

Yeah. Okay. On the poly-users, I think that we mentioned we give some statistics about vapor compared with HP in a conference that we participated last year. And we don't see a massive material change amongst those two categories in what conversion is related. So we don't agree with this comment about one has a much stronger conversion than others in the first place. And it's good to remember that vapor is 65% of consumption in this new space of no combustibles to start with and is growing fast as well, different from THP, which is, if anything, is slowing down as a category, mostly because of the phenomenon of poly-users. That is not just because of vapor, but now a very accelerated growth in terms of Modern Oral. In terms of U.S. vapor, what we quoted before is a number around 2% of decline that is linked directly with the proliferation of these illegal products. If anything, we haven't seen any type of reduction in terms of growth. I cannot be here in a position to say, all these headlines that you read has reflected positively in the market because we don't see this should be the case. Actually, the likely loss of share that we had in vapor. It was exactly for these illegal products in the tracked channels mostly. So they still continue to grow. There is -- it's very difficult to answer a question of when we expect to see enforcement because we were expecting to see a conclusion of the PMTA vapor process from the FDA perspective end of June, where originally it was end of December last year and now moved to end of June. So -- we still haven't seen that. That's why in my presentation was make a reference to the needs of the FDA to really conclude this process and be able to clearly publicly state what is allowed, what is not allowed because this can help tremendously enforcement, at least on these tracked channels that we are continuing to see growing the participation of illegal vapors. Now Louisiana is the state of the art in terms of regulation. So we are seeing a big progress in terms of reduction of Indigo products there, and which has benefited substantially Vuse as a major beneficiary with a reduction on the illegal products. And the other two, not at the same level because, as I mentioned, they are not the same type of regulations. But it's a good start point because what you could do is to improve the regulation as soon as you start that. But in the other two states, although there are some reduction, not at the same level of Louisiana because Louisiana is a more complete because they have just introduced also an excise, they use this to fund proper enforcement in the legislation. And they have -- if you see the details around the legislation is much more, I would say, comprehensive than the other two states.

Thanks, Tadeu.

Thank you. And we now take a question from Damian McNeela of Deutsche Bank. Please go ahead.

Hi, good morning, everybody. Two for me, please. Just firstly, just on the U.S. combustibles business. You've indicated that contracted coverage has moved from 82% to 88% just wondering what a reasonable level of coverage would be for the U.S. and how long it would take you to get there. And then just more generally on how happy you are with the progress that's being made in the commercial organization in the U.S. and whether there's any more that can be done to drive an improvement in performance there? And then the second question is just on, Soraya indicated an incremental GBP50 million going into Modern Oral capacity. I was just wondering if you could give us an indication of how much headroom those investments gave you going forward, please.

Okay. Yeah. On the coverage, it's always an assessment of the investment and the return that we get on those retailers. We are coming to a point that we are very satisfied where we are -- that's why I was referring to. Most of the commercial plans has been already concluded. We did that back of increasing our sales force by 150 new reps, and so we expanded our sales force in order to do that. We also invest heavily even more in terms of data analytics, revenue growth management systems in general. And these are part of the commercial plans together with laddering and price adjustments and so on. So we are pretty much there in terms of what we need to do. You saw some of the improvements that we have been achieving recently in terms of volume share in terms of value share, in terms of premium segment. And so I think that we are in a very strong position now to benefit from when the market starts to improve from the macroeconomic level and from the enforcement levels on the on the illicit products. But it's important to notice that nicotine consumption in the U.S. is still pretty stable. The problem is that it's growing where we are not able to participate nowadays. Of course, these illegal vapor markets accounting to -- and I mentioned this before, more than 6% of the vapor category, which means around GBP60 billion of revenue that will be up for grabs as soon as we have some minimal enforcement in that space, not to mention the emergency of Modern Oral as well as a category that we are now, despite the fact that we don't have our winning products that is still in the U.S., but subject to PMTA approval, as you know. We are being able to start making some inroads to the product that we have currently after some adjustments that we have done more recently. Modern Oral is a category that is growing everywhere. And you'll probably notice in our comment that 25% of the markets outside -- of the industry are in place where there was no oral tradition before, and this materialized in the massive growth. And BAT, with our product-to-bill is being able to absorb more than 7% of this growth happening in AME outside the U.S. So we are really, really well positioned and having a truly powerful brand that consumer loves and being very well activated. And hopefully, together with some improvements we are doing in the U.S. and mostly when we'd really be able to have this product in the U.S., this will be a fantastic opportunity for the group moving forward. I will leave for Soraya to answer about the CapEx.

In terms of the CapEx, yes, we're always enhancing. As you can see, the trajectory of Modern Oral has been very impressive. I mean, on the first half alone, we grew 47%. So we're always looking to further invest to enhance capacity, both for the U.S. and in Europe. So we have revised our CapEx investment this year from GBP550 million to GBP600 million.

Okay. Thank you.

Thank you. And with that, I'd like to hand the call back over to you, Victoria, for any questions via the webcast.

Thank you. We do have a couple of questions from the web. Soraya, this one is probably for you. How much of the raw material increase was leaf costs versus FX? And how much do you expect this to unwind over the next six months and over the next year?

Okay. We had significant increase in leaf costs. I think it was -- the raw materials was around 9% to 10%, and the leaf was around 14%. This is coming down sharply in the second half, and we expect most of it to unwind by next year. But it has been a drag on the overall operating margin or the gross margin in terms of combustibles, which hopefully will be an upside for us next year.

Next question is, will the [Indiscernible] payments impact our buyback plans next year?

Okay. So the [Indiscernible] payments, which is GBP0.8 billion over four years, the amounts yearly have been well known to us, and they have been fully taken into account in our forecast when we actually announced our buyback resulting from the sale of our ITC stake. And we committed to GBP700 million, which we started in March, and we will be doing the buyback of the remaining GBP900 million to make up the GBP1.6 billion from the ITC stakes out. End of Q&A:

So apologies, we don't appear to have any more questions from the web. If you didn't manage to ask a question, then please don't hesitate to contact the IR team and we'd be delighted to help you. So I'd now hand back to Tadeu for some closing remarks.

Okay. Thank you for listening today and for your questions. I hope you can all see this year is a key moment in our transformation journey. I'm confident that the target investment choice we are making and the right decisions to deliver long-term growth and value creation. I look forward to keeping you updated on our progress, and I hope to see many of you at our Capital Markets Day being held at our innovation center in South Hampton on the 16th of October. Here, you have the opportunity to see firsthand how our teams are focused on reducing the health impact of our business and enabling BAT to deliver long-term sustainable value for all our stakeholders. Thank you very much.